News articles about Celgene Corporation (NASDAQ:CELG) have been trending somewhat positive this week, Accern Sentiment reports. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Celgene Corporation earned a media sentiment score of 0.24 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 76 out of 100, indicating that recent media coverage is likely to have an impact on the stock’s share price in the immediate future.
Here are some of the news articles that may have effected Accern Sentiment’s analysis:
- NEW 52 Week High, NASDAQ, June 22 – ALNY, IBUY, RILYZ, BGNE, BVXV, BBP, BL, BRKR, CA, CPRX, CELG, CELH, CLVS, CTSH, CACC (fxpips.com)
- Celgene Corporation (CELG) Insider Sells $575061.30 in Stock (eleganthomesinla.com)
- Celebrated Photographer Martin Schoeller Shines a Light on People With Psoriatic Disease Including Olympic Swimmer and Author Dara Torres as Part of Celgene’s SHOW MORE OF … (businesswire.com)
- Celgene Corp. (CELG) Climbed To A New High For The Year (rttnews.com)
- Celgene Corporation (CELG) Saw a New 52-Week High (highlightpress.com)
Shares of Celgene Corporation (CELG) traded up 1.04% during midday trading on Thursday, hitting $134.21. 3,635,075 shares of the company’s stock were exchanged. The stock’s 50 day moving average is $119.20 and its 200-day moving average is $119.73. The stock has a market cap of $104.79 billion, a PE ratio of 50.40 and a beta of 1.82. Celgene Corporation has a 1-year low of $94.42 and a 1-year high of $134.93. Celgene Corporation also saw some unusual options trading activity on Wednesday. Traders purchased 1,270 put options on the company. This represents an increase of approximately 232% compared to the typical daily volume of 382 put options.
Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, April 27th. The biopharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.47 by $0.21. The company had revenue of $2.96 billion for the quarter, compared to analyst estimates of $3.04 billion. Celgene Corporation had a net margin of 18.32% and a return on equity of 70.94%. The business’s quarterly revenue was up 17.8% on a year-over-year basis. During the same quarter last year, the firm posted $1.32 earnings per share. Analysts predict that Celgene Corporation will post $7.29 earnings per share for the current fiscal year.
Several equities analysts have weighed in on CELG shares. Jefferies Group LLC reiterated a “buy” rating and issued a $154.00 target price on shares of Celgene Corporation in a report on Tuesday, April 11th. Cann reiterated a “buy” rating and issued a $148.00 target price on shares of Celgene Corporation in a report on Tuesday, April 4th. Oppenheimer Holdings, Inc. set a $148.00 target price on shares of Celgene Corporation and gave the company a “buy” rating in a report on Saturday, February 25th. Canaccord Genuity set a $156.00 target price on shares of Celgene Corporation and gave the company a “buy” rating in a report on Saturday, February 25th. Finally, Cantor Fitzgerald set a $159.00 target price on shares of Celgene Corporation and gave the company a “buy” rating in a report on Thursday, April 27th. One analyst has rated the stock with a sell rating, six have issued a hold rating, twenty have given a buy rating and one has assigned a strong buy rating to the company’s stock. Celgene Corporation has an average rating of “Buy” and a consensus price target of $139.49.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive Media Coverage Likely to Affect Celgene Corporation (CELG) Stock Price” was first published by sleekmoney and is owned by of sleekmoney. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://sleekmoney.com/somewhat-positive-media-coverage-likely-to-affect-celgene-corporation-celg-stock-price/1931272.html.
In other news, insider Rupert Vessey sold 4,785 shares of Celgene Corporation stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $120.18, for a total transaction of $575,061.30. Following the sale, the insider now owns 4,004 shares in the company, valued at $481,200.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gilla Kaplan sold 14,033 shares of Celgene Corporation stock in a transaction that occurred on Thursday, March 30th. The shares were sold at an average price of $123.83, for a total transaction of $1,737,706.39. Following the sale, the director now owns 73,109 shares in the company, valued at approximately $9,053,087.47. The disclosure for this sale can be found here. Insiders have sold 37,318 shares of company stock worth $4,621,475 in the last quarter. Insiders own 0.95% of the company’s stock.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/somewhat-positive-media-coverage-likely-to-affect-celgene-corporation-celg-stock-price/1931272.html
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.